PMN Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-18.600.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$93.1MMicro cap

Wall Street coverage

$34.65median target· current $38.75 (-10.6%)5 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
PEG ratio
P/B
1.53
P/S (TTM)
4016.22
EV/EBITDA
-1.74

Profitability & growth

ROE (TTM)
-115.7%
Operating margin
0.0%
Revenue growth YoY
0.0%
Dividend yield
Beta
-0.17
Last earnings
May 12, 2026 · Estimate $-0.21 · Reported $-1.26
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Utilizing its proprietary protein engineering platform, ProMIS specializes in the identification and targeting of misfolded proteins associated with these diseases, which enhances the safety and efficacy of its drug candidates. The company boasts a robust and diverse pipeline of candidates in various stages of development, positioning it favorably to…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
1920 YONGE STREET, TORONTO, ON
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$93.1M
Shares outstanding$9.0M
52W high$39.75
52W low$6.27

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer